Insys Therapeutics In-Licenses Cannabinoid Inhalation

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Insys Therapeutics In-Licenses Cannabinoid Inhalation Technology

PHOENIX, AZ--(Marketwired - Sep 24, 2015) - Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that it has entered into an exclusive license agreement and partnership with U.K. based Senzer Ltd. for the development of inhaled synthetic pharmaceutical cannabinoid products including dronabinol ("THC") and cannabidiol ("CBD") using Senzer's proprietary inhalation delivery technology.

"The Senzer technology involves no heat or combustion and as a result produces no ash or smoke. It also doesn't require a battery or other energy source and is activated simply by the user's inhalation. We are excited to be working with Insys to potentially deliver synthetic pharmaceutical cannabinoids, such as THC and CBD in this unique inhalation system," said Alex Hearn, Chief Executive Officer of Senzer and the inventor of the technology.

Senzer has exclusively licensed all proprietary inhalation delivery technology in the field of Cannabinoid molecules (and the intellectual property related thereto) held by Kind Consumer Holdings Limited, a UK based healthcare research and development company focused on inhalation technologies. The Kind Consumer inhalation technology has been recently approved by the Medicines and Healthcare products Regulatory Agency ("MHRA") in the United Kingdom as a licensed medicine ("Voke Inhaler®") for smoking cessation. Insys and Senzer will work towards the development of synthetic pharmaceutical THC and CBD inhaled products under the guidance of the U.S. Food and Drug Administration ("FDA") using the same inhalation technology as used in the Voke Inhaler product.

"This unique inhalation delivery technology will complement our portfolio of in-market products, and developmental-stage synthetic pharmaceutical cannabinoids and sublingual sprays. With our commitment to cannabinoids, we believe this partnership is a step forward to potentially establish Insys as a frontrunner in this arena," said Michael Babich, President and Chief Executive Officer.

"The incorporation of Insys' synthetic pharmaceutical THC and CBD into this non-heat, pressure-based technology for inhalation delivery has the potential to enhance their efficacy in supportive cancer care. I believe it can also further advance Insys Therapeutics as an outright innovator and leader in this critically important area of cancer management," said David S. Alberts, MD., Director Emeritus, University of Arizona Cancer Center.

Both CBD and THC have potential usage in the cancer populations. THC, currently available as an FDA approved capsule (Marinol® and generic versions), is indicated for nausea and vomiting associated with chemotherapy in adults. Preclinical studies suggest that CBD may have applications in glioblastoma multiforme and chemotherapy induced neuropathic pain. Besides oncology, CBD has the potential to provide new treatment options for a wide variety of diseases, such as epilepsy, brain cancer, schizophrenia, post-traumatic stress disorder, anxiety, Alzheimer's disease, neuropathic pain, Parkinson's disease, addiction, diabetes, and many others.

Company Expands Research and Development Team

Insys also announced that it has recently hired new key managers with substantial pharmaceutical and manufacturing experience to advance this project. Lein-Lung (LL) Sheu, Ph.D. joins Insys as Senior Vice President, Manufacturing, where his responsibilities will include overseeing the Insys cannabinoid manufacturing facility. Dr. Sheu brings over two decades of manufacturing experience with pharmaceutical companies such as Ikaria, Inc. and Baxter International, where he oversaw global supply chain operations. Additionally, Brent Donovan, Ph.D., Senior Director, Pharmaceutical Research, and Oscar Liu, Ph.D., Director, Pharmaceutical Research, both join Insys with over thirty years of collective experience in inhalation and oral drug delivery development experience with companies such as Merck, Par Pharmaceutical and Pfizer Inc.

"We welcome LL, Brent and Oscar to our team at Insys. We look forward to their contributions as we continue to advance our trajectory as a fully-integrated pharmaceutical company with in-house research and development, manufacturing and commercialization capabilities," concluded Babich.

About Insys Therapeutics, Inc. Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys strives to address the clinical shortcomings of existing commercial products. The Company recently submitted a New Drug Application to the U.S. Food and Drug Administration for Dronabinol Oral Solution, a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is developing a pipeline of sublingual sprays, as well as synthetic pharmaceutical cannabidiol.

Subsys® is a registered trademark of Insys Therapeutics, Inc.

About Senzer Ltd. Senzer Ltd. is a U.K. based innovative inhalations technology company specializing in development and commercialization of therapeutic delivery systems of cannabinoid products, and is developing a pipeline of inhalation products to meet unmet medical needs. Senzer Ltd. is addressing in particular the need for development of rapid onset inhaled delivery without heat, combustion or electronics to deliver pharmaceutically active cannabinoids, as well as other active pharmaceutical and formulations.

Forward-Looking Statements This press release contains forward-looking statements including statement related to believes or expectations that the Senzer technology can potentially deliver synthetic pharmaceutical cannabinoids and has potential usage in cancer populations or for other applications or diseases and that Insys is a potential leader in synthetic pharmaceutical cannabinoids, as well as the statement that we believe that our Dronabinol Oral Solution has distinct advantages over the current formulation of dronabinol in soft gel capsule These forward-looking statements are based on management's expectations and assumptions as of the date of this press release; actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. These factors include, but are not limited to risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2014 and subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this press release and we undertake no obligation to publicly update or revise these statements, except as may be required by law.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 489

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 114

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 775

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Luca's Campo Morado Denial Makes Guerrero Risk Clear

Updated Category News Views 94

A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 106

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 130

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 221

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 292

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
CommBank Yello Builds a Wider Moat Around Customers

Updated Category News Views 23

Nine million customers is not a pilot program; it is a crowded stadium, and CommBank has decided to hand everyone a reason to stay in their seats. Commonwealth Bank's expanded CommBank Yello program now lets eligible customers earn points across home loans, term deposits, cards and insurance, then redeem with well-known brands. That is a serious attempt to make a bank...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating Global Voices: WAC conference speaker lineup

Updated Category News Views 322

Premier Speakers Set to Inspire at the World Affairs Conference Excitement continues to build for the upcoming World Affairs Conference (WAC), attracting attention from students and educators alike. This prestigious event promises a day filled with thought-provoking discussions and insights from renowned speakers, including Bill Weir, Keith Pelley, and Dr. James Orbinski....

Continue Reading
Transform Your Investment Journey With Westinghouse Air Brake

Updated Category News Views 166

Long-Term Growth of Westinghouse Air Brake Understanding the remarkable growth of Westinghouse Air Brake is essential for current and prospective investors. Over the elapsed two decades, this company has consistently outperformed the market, achieving an impressive annualized growth rate of 14.54%. Cumulative Return on Investment If one had invested $100 in Westinghouse...

Continue Reading
Revitalizing Healthcare: Bipartisan Efforts to Combat Sepsis

Updated Category News Views 179

Revitalizing Healthcare Efforts with the SEPSIS Act In a significant move to address one of the most critical health challenges facing the nation today, the SEPSIS Act has been reintroduced in the Senate. This bipartisan legislation aims to tackle the sepsis crisis—a pressing issue that affects countless families and places a heavy burden on healthcare resources. With a...

Continue Reading
Transforming Innovation: The Charles Huang Initiative in Glasgow

Updated Category News Views 256

Revitalizing Education and Innovation The Charles Huang Foundation (CHF) has announced a transformative project at the University of Strathclyde, aiming to bolster educational and entrepreneurial efforts through a £30 million investment. This funding will be pivotal in converting a former Student Union building on John Street into the Charles Huang Advanced Technology &...

Continue Reading
Ally Waste Chosen for Valet Trash Services by RangeWater Real Estate

Updated Category News Views 190

Ally Waste Partners with RangeWater Real Estate for Waste Solutions Ally Waste, a prominent provider of valet trash services and various onsite waste solutions for multifamily communities, has been selected as the preferred valet trash service provider for RangeWater Real Estate. This decision comes after a meticulous evaluation of potential service partners through a...

Continue Reading